5875
CONCLUSIONS : Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus .
 adverse effect: carotid insufficiency, bevacizumab; adverse effect: coagulopathy, bevacizumab; adverse effect: poorly controlled diabetes mellitus, bevacizumab
Given options, please tell me the relationships of all the listed entity pairs.Output format is "relation1: word1, word2; relation2: word3, word4". 
Option: adverse effect 
Text: {0} 
 Entity Pairs:  carotid insufficiency, bevacizumab; coagulopathy, bevacizumab; poorly controlled diabetes mellitus, bevacizumab 
Answer:
 adverse effect: carotid insufficiency, bevacizumab; adverse effect: coagulopathy, bevacizumab; adverse effect: poorly controlled diabetes mellitus, bevacizumab